The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.
Poto R, Cristinziano L, Criscuolo G, Strisciuglio C, Palestra F, Lagnese G, Di Salvatore A, Marone G, Spadaro G, Loffredo S, Varricchi G.
Poto R, et al. Among authors: criscuolo g.
Front Immunol. 2024 Aug 12;15:1443704. doi: 10.3389/fimmu.2024.1443704. eCollection 2024.
Front Immunol. 2024.
PMID: 39188724
Free PMC article.